BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 34591728)

  • 1. Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions.
    Repetto M; Crimini E; Giugliano F; Morganti S; Belli C; Curigliano G
    Expert Rev Clin Pharmacol; 2021 Oct; 14(10):1233-1252. PubMed ID: 34591728
    [No Abstract]   [Full Text] [Related]  

  • 2. Future applications of FGF/FGFR inhibitors in cancer.
    Ghedini GC; Ronca R; Presta M; Giacomini A
    Expert Rev Anticancer Ther; 2018 Sep; 18(9):861-872. PubMed ID: 29936878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors.
    Hierro C; Rodon J; Tabernero J
    Semin Oncol; 2015 Dec; 42(6):801-19. PubMed ID: 26615127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.
    Ronca R; Giacomini A; Rusnati M; Presta M
    Expert Opin Ther Targets; 2015; 19(10):1361-77. PubMed ID: 26125971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
    Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
    Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications.
    Helsten T; Schwaederle M; Kurzrock R
    Cancer Metastasis Rev; 2015 Sep; 34(3):479-96. PubMed ID: 26224133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.
    Nakanishi Y; Akiyama N; Tsukaguchi T; Fujii T; Sakata K; Sase H; Isobe T; Morikami K; Shindoh H; Mio T; Ebiike H; Taka N; Aoki Y; Ishii N
    Mol Cancer Ther; 2014 Nov; 13(11):2547-58. PubMed ID: 25169980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.
    Chell V; Balmanno K; Little AS; Wilson M; Andrews S; Blockley L; Hampson M; Gavine PR; Cook SJ
    Oncogene; 2013 Jun; 32(25):3059-70. PubMed ID: 22869148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications.
    Dianat-Moghadam H; Teimoori-Toolabi L
    Curr Drug Targets; 2019; 20(8):852-870. PubMed ID: 30648505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors.
    Salgia R
    Cancer Med; 2014 Jun; 3(3):681-92. PubMed ID: 24711160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
    Roskoski R
    Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
    Katoh M
    Int J Mol Med; 2016 Jul; 38(1):3-15. PubMed ID: 27245147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The FGF/FGFR signalling mediated anti-cancer drug resistance and therapeutic intervention.
    Mahapatra S; Jonniya NA; Koirala S; Ursal KD; Kar P
    J Biomol Struct Dyn; 2023; 41(22):13509-13533. PubMed ID: 36995019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGFR a promising druggable target in cancer: Molecular biology and new drugs.
    Porta R; Borea R; Coelho A; Khan S; Araújo A; Reclusa P; Franchina T; Van Der Steen N; Van Dam P; Ferri J; Sirera R; Naing A; Hong D; Rolfo C
    Crit Rev Oncol Hematol; 2017 May; 113():256-267. PubMed ID: 28427515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the fibroblast growth factor receptor family in cancer.
    Hallinan N; Finn S; Cuffe S; Rafee S; O'Byrne K; Gately K
    Cancer Treat Rev; 2016 May; 46():51-62. PubMed ID: 27109926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
    André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
    Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologically targeting the myristoylation of the scaffold protein FRS2α inhibits FGF/FGFR-mediated oncogenic signaling and tumor progression.
    Li Q; Alsaidan OA; Ma Y; Kim S; Liu J; Albers T; Liu K; Beharry Z; Zhao S; Wang F; Lebedyeva I; Cai H
    J Biol Chem; 2018 Apr; 293(17):6434-6448. PubMed ID: 29540482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.
    Tan L; Wang J; Tanizaki J; Huang Z; Aref AR; Rusan M; Zhu SJ; Zhang Y; Ercan D; Liao RG; Capelletti M; Zhou W; Hur W; Kim N; Sim T; Gaudet S; Barbie DA; Yeh JR; Yun CH; Hammerman PS; Mohammadi M; Jänne PA; Gray NS
    Proc Natl Acad Sci U S A; 2014 Nov; 111(45):E4869-77. PubMed ID: 25349422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.
    Watanabe Miyano S; Yamamoto Y; Kodama K; Miyajima Y; Mikamoto M; Nakagawa T; Kuramochi H; Funasaka S; Nagao S; Sugi NH; Okamoto K; Minoshima Y; Nakatani Y; Karoji Y; Ohashi I; Yamane Y; Okada T; Matsushima T; Matsui J; Iwata M; Uenaka T; Tsuruoka A
    Mol Cancer Ther; 2016 Nov; 15(11):2630-2639. PubMed ID: 27535969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural Alterations in Human Fibroblast Growth Factor Receptors in Carcinogenesis.
    Mikhaylenko DS; Alekseev BY; Zaletaev DV; Goncharova RI; Nemtsova MV
    Biochemistry (Mosc); 2018 Aug; 83(8):930-943. PubMed ID: 30208830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.